Affiliations: [a] Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA | [b] Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA | University of North Carolina, Chapel Hill, NC, USA
Correspondence:
[*]
Corresponding author: Lisa A. Carey, M.D., Associate Professor, University of North Carolina at Chapel Hill, Division of Hematology/Oncology, CB#7305, 3009 Old Clinic Bldg., Chapel Hill, NC 27599-7305, USA. Tel.: +1 919 966 8218; Fax: +1 919 966 6735; E-mail: Lisa_Carey@med.unc.edu
Abstract: About a third of all newly diagnosed breast cancers occur in women under the age of 50 [1,2]. Young women face many of the same adjuvant treatment issues that their postmenopausal counterparts encounter. Unfortunately, they also experience issues that are unique to their age, their hormonal status, and their longer life expectancy. We will examine the issues regarding cytotoxic and biologic therapy as well as the controversies regarding optimal endocrine and chemoendocrine therapy in the premenopausal woman, and we will explore some of the survivorship issues faced by young women after breast cancer therapy.
DOI: 10.3233/BD-2006-23109
Journal: Breast Disease, vol. 23, no. 1, pp. 67-71, 2006
